In a dose-finding phase 1 trial, Fuxius et al [40] combined gemcitabine at maximum tolerated dose (MTD) 1000 mg/m2 with IFN-α-2b 3 × weekly (MTD 5 × 106 IU) for 3 consecutive weeks followed by 1 week of rest (28-day cycles) in patients with solid tumors, including one patient with ovarian cancer. Here, IFNA2 is linked to ovarian cancer.